Background and purpose: Serum neurofilaments are markers of axonal injury. We addressed their diagnostic and prognostic role in acute ischemic stroke (AIS) and transient ischemic attack (TIA). Methods: Nested within a prospective cohort study, we compared levels of serum neurofilament light chain (sNfL) drawn within 24 h from symptom onset in patients with AIS or TIA. Patients without magnetic resonance imaging on admission were excluded. We assessed whether sNfL was associated with: (i) clinical severity on admission, (ii) diagnosis of AIS vs. TIA, (iii) infarct size on admission magnetic resonance diffusion-weighted imaging (MR-DWI) and (iv) functional outcome at 3 months. Results: We analyzed 504 patients with AIS and 111 patients with TIA. On admission, higher National Institutes of Health Stroke Scale (NIHSS) scores were associated with higher sNfL: NIHSS score < 7, 13.1 pg/mL [interquartile range (IQR), 5.3-27.8]; NIHSS score 7-15, 16.7 pg/mL (IQR, 7.4-34.9); and NIHSS score > 15, 21.0 pg/mL (IQR, 9.3-40.4) (P = 0.01). Compared with AIS, patients with TIA had lower sNfL levels [9.0 pg/mL (95% confidence interval, 4.0-19.0) vs. 16.0 pg/mL (95% confidence interval, 7.3-34.4), P < 0.001], also after adjusting for age and NIHSS score (P = 0.006). Among patients with AIS, infarct size on admission MR-DWI was not associated with sNfL, either in univariate analysis (P = 0.15) or after adjusting for age and NIHSS score on admission (P = 0.56). Functional outcome 3 months after stroke was not associated with sNfL after adjusting for established predictors. Conclusions: In conclusion, among patients admitted within 24 h of AIS or TIA onset, admission sNfL levels were associated with clinical severity on admission and TIA diagnosis, but not with infarct size on MR-DWI acquired on admission or functional outcome at 3 months.
Introduction
Blood markers of acute brain injury may help in the management of patients with acute cerebrovascular events. Blood markers may help to discern patients with an acute ischemic stroke (AIS) and those with a transient ischemic attack (TIA), serve as a surrogate marker of acute infarct size, and improve models predicting functional outcome.
Neurofilaments are 10-nm polypeptide filaments that constitute a major component of the axonal cytoskeleton. Neurofilaments consist of at least three subunits: light chain, medium chain and heavy chain, and alpha-internexin [1] . After neuroaxonal injury, neurofilaments are released into the extracellular space, cerebrospinal fluid and peripheral blood [1] . In peripheral blood, reliable detection of the neurofilament light-chain samples has become possible only in recent years [2] . Serum neurofilament light chain (sNfL) has been shown to be a marker of injury in a number of chronic neurological disorders, including multiple sclerosis [3] , frontotemporal dementia [4] and amyotrophic lateral sclerosis [5] , and in some acute neurological disorders such as acute spinal injury [6] and traumatic brain injury [7] . However, in AIS and TIA, the role of sNfL has not yet been investigated in large study populations. In this prospective cohort study, we assessed whether sNfL is associated with: (i) clinical severity on admission, (ii) diagnosis of AIS vs. TIA, (iii) infarct size on admission magnetic resonance diffusion-weighted imaging (MR-DWI) and (iv) functional outcome at 3 months. A control group was included.
Patients and methods

Ethics statement
This study (ClinicalTrials.gov: NCT00878813) was approved by the Ethics Committee of the University of Bern. All patients or their welfare guardians provided written informed consent for the collection of data, blood samples and subsequent analyses.
Study design, inclusion and exclusion criteria
This was a prospective cohort study nested within the CoRisk Study, a multicenter prospective cohort study described previously (ClinicalTrials.gov: NCT00878813) [8] . In the CoRisk study, we included consecutive patients >18 years of age with AIS or TIA within 24 h of symptom onset, admitted to the emergency department of the University Hospitals of Bern, Basel and Frankfurt am Main between 24 March 2009 and 8 April 2011.
Inclusion and exclusion criteria
For this nested cohort study, we selected patients admitted to the University Hospital Bern, representing the majority of the CoRisk cohort (934/1085, 86%), with a diagnosis of AIS or TIA. AIS was defined as neurological dysfunction lasting >24 h with an acute lesion on MR-DWI and no acute intracranial bleeding. TIA was defined as neurological dysfunction lasting ≤24 h and caused by focal brain ischemia without an acute lesion on MR-DWI (a modified tissue-based definition) [9] . To discriminate AIS from TIA, and to reliably assess the size of the acute infarct and sNfL, we excluded patients without magnetic resonance imaging on admission day (n = 270). Finally, we excluded patients with symptoms lasting >24 h but no acute infarct on MR-DWI, as they could be classified as neither AIS nor TIA (n = 39), as well as patients with insufficient serum left to measure sNfL (n = 10).
The control group consisted of volunteers aged between 18 and 70 years, without any known neurological disease. Information on cardiovascular risk factors was not available for the control group.
Size estimation of acute infarct
All magnetic resonance imaging was acquired prior to thrombolysis, if thrombolysis was performed. Infarct sizes on MR-DWI were estimated by consensus of two experienced raters unaware of the clinical and laboratory findings. Infarct size was estimated by a commonly used semi-quantitative method validated for acute infarcts [10] . Infarct sizes were categorized into: (i) small infarct (volume <10 cm 3 ), (ii) medium infarct (10-100 cm 3 ) and (iii) large infarct (volume >100 cm 3 ).
Functional outcome
Trained stroke physicians and study nurses assessed functional outcome 3 months after the acute stroke, either during an outpatient visit or with a structured follow-up telephone interview. Unfavorable functional outcome was defined as a modified Rankin Scale score of between 3 and 6 [11] .
Biomarker measurement
Blood was drawn in the emergency room upon admission (day 0). To study the temporal evolution of sNfL levels, a subset of patients who underwent thrombolysis received a second blood sampling after 24 h (day 1). After centrifugation for 20 min at 3000 g at room temperature, serum (from ethylenediaminetetra-acetic acid tube) was aliquoted. Tubes were frozen locally at -70°C. sNfL concentrations were measured in duplicate by a previously described and slightly modified electrochemiluminescence immunoassay [2] . For further details please see Data S1.
Statistics
Discrete variables were expressed as counts (percentages) and continuous variables as medians [interquartile range (IQR)]. The distribution of raw sNfL levels was skewed. After log transformation with base of 10 of sNfL levels, the distribution of raw sNfL levels approximated a normal distribution. To compare variables, we used Fisher's exact test (for categorical data), Mann-Whitney U-test (for unmatched continuous data) and Snedecor-Cochran test (for matched continuous data, i.e. sNfL levels of day 0 to day 1). To assess the independent association of sNfL with dichotomous endpoint (i.e. AIS vs. TIA), we computed multivariate logistic regression models adjusted for established predictors.
Ordinal regression models were used to explore the association between sNfL and ordinal endpoints [i.e. National Institutes of Health Stroke Scale (NIHSS) categories and infarct size]. Linear regression models were used to explore the association between two continuous variables [e.g. log(sNfL) and hours between symptom onset and venipuncture]. We report odds ratios along with 95% confidence intervals (CIs) as measures of association and uncertainty, respectively.
Sensitivity and specificity of sNfL were calculated based on receiver-operating characteristic curve (Cstatistics). Testing was two-sided and P < 0.05 was considered to indicate statistical significance. Statistics were calculated using Stata Statistical Software: Release 14.2 (StataCorp, College Station, TX, USA).
Results
We included 504 patients with AIS, 111 with TIA and 165 volunteers in the control group. Table 1 details the baseline characteristics including sNfL levels of patients with AIS or TIA. In the control group, median age was 48 years (IQR, 38-56), and 110 volunteers were women (67%). The control group had lower sNfL levels than patients with AIS or TIA [2.5 pg/mL (IQR, 0.4-5.4) vs. 15.0 pg/mL (IQR, 6.1-31.8), P adjusted for age < 0.001]. On admission of patients with AIS or TIA, higher NIHSS scores were associated with higher sNfL [NIHSS score < 7, 13.1 pg/mL (IQR, 5.3-27.8); NIHSS score 7-15, 16.7 pg/mL (IQR, 7.4-34.9); NIHSS score > 15, 21.0 pg/mL (IQR, 9.3-40.4), P for trend = 0.03, adjusted for age, etiology and time between symptom onset and venipuncture]. Compared with AIS, patients with TIA also had lower sNfL levels after adjusting for age and NIHSS score (P = 0.006, Tables 1 and 2 ). However, the association magnitude between sNfL and TIA was moderate, with an area under the curve of sNfL of 0.64 (95% CI, 0.58-0.69, P < 0.001), indicating that 36% of patients with TIA will actually have higher sNfL than patients with AIS. Among patients with AIS, infarct size on admission MR-DWI was not associated with sNfL, either in univariate analysis (P = 0.15) or after adjusting for age and NIHSS score on admission (P = 0.56) ( Table 2 , Fig. 1) .
Within the first 24 h after symptom onset, the delay from stroke onset to venipuncture was not associated with either sNfL levels in the unadjusted analysis (R 2 = 0.00, P = 0.67) or in the analysis adjusted for stroke severity on admission (adj. R 2 = 0.01, P = 0.71), with no difference across the three subgroups stratified by infarct size (P for interaction = 0.47). Among patients with AIS and TIA, sNfL was not significantly associated with leucocytes (P = 0.23) or C-reactive protein (P = 0.12). At 24 h after admission, 84 out of 190 patients (44%) with AIS undergoing thrombolysis had a second venipuncture to assess sNfL. Median sNfL levels were 13.7 pg/mL (IQR, 7.0-27.2) before thrombolysis and 17.1 pg/mL (IQR, 9.6-35.3, P = 0.06) 24 h later. A statistically significant increase in sNfL from the admission day to the following day was seen only in the subgroup with a large infarct size on admission (n = 16), where sNfL increased from 12.9 pg/mL (IQR, 6.9-32.6) to 38.6 pg/mL (IQR, 20.1-112.5, P = 0.02) (Fig. 2) . Any increase in sNfL levels from day 0 to day 1 (n = 51, 61%) had a sensitivity of 81% and specificity of 44% for a large infarct size [area under the curve, 0.78 (95% CI, 0.63-0.92)]. After adjusting for age and NIHSS score, patients with the greatest increase in sNfL from day 0 to day 1 (fourth vs. first quartile of increase) had an almost fivefold higher chance of having a larger infarct size on admission MR-DWI (odds ratio, 4.72; 95% CI, 1.10-20.30, P = 0.04).
At 3 months, follow-up information was available for 487 of the 504 patients classified as having AIS (follow-up rate, 97%). A poor functional outcome was observed in 153 patients (30%). Their baseline sNfL levels were more than twice as high as in patients with good functional outcome [26 pg/mL (IQR, 13-47) vs. 13 pg/mL (IQR, 6-30), P < 0.001]. After adjusting for age, NIHSS score and the infarct size on MR-DWI, sNfL was not significantly associated with functional outcome at 3 months (Table 2) .
Discussion
In this cohort study, patients with AIS or TIA had higher sNfL levels than volunteers without neurological diseases. Clinical severity on admission was associated with sNfL levels in the first 24 h after stroke onset. sNfL levels discriminated moderately for the diagnosis of TIA versus AIS, i.e. absence versus presence of an infarct on MR-DWI. These findings support the concept that sNfL mirrors axonal damage. Among patients with AIS, infarct size on MR-DWI was not significantly associated with sNfL levels, at least on blood drawn on admission. From admission day to the following day, patients with large infarcts on MR-DWI had a significant increase in sNfL levels, suggesting that sNfL levels peak only after several days. The 3-month outcome was not associated, after adjusting for established predictors, with sNfL levels on admission.
As in our study, two previous studies compared patients with AIS with healthy controls, and found higher blood neurofilament levels among patients with AIS [12, 13] . Among patients with AIS, two previous studies observed a significant association between clinical severity on admission and blood neurofilament [12, 14] . A study with 18 patients with AIS found no significant association between NIHSS score and serum neurofilament (sNf), a finding that was probably due to statistical underpowering [13] . In our study, patients with TIA had 1.7-fold lower sNfL compared with patients with AIS, whereas a study on patients with non-traumatic cervical artery dissection found 6.6-fold lower sNfL in patients with TIA compared with patients with AIS. In the latter study, sNfL was assessed within 30 days from symptom onset [14] , i.e. later than in our study, in which sNfL was assessed on admission in all patients [14] . During the longer time interval, more neurofilament light chain is released from damaged axons into the bloodstream, a phenomenon that may explain the greater difference between TIA in AIS seen when sNfL is assessed in blood drawn up to 30 days from symptom onset.
In our study, the lack of association between infarct size on MR-DWI and sNfL levels on admission apparently contrasts with a previous cohort study with patients with AIS, where serum neurofilament heavy chain (sNfH) levels did correlate with infarct size on magnetic resonance imaging, available in 17 patients [12] . However, in our study, the median time interval between AIS onset and the first blood sample (2.8 h) was shorter than in the cited study (7-10 days after stroke onset) [12] . Again, this observation suggests a delay in the increase of sNf levels after AIS, weakening the association between infarct size and sNfL assessed in blood drawn as early as 24 h after symptom onset. Moreover, it is possible that sNfL levels rise faster in patients with large, rather than small, infarcts. In support of this view, we found a significant sNfL increase from day 0 to day 1 only among patients with large infarcts. Although we did not have longitudinal blood samples after day 1, sNfH reached its peak at week 3 in 80% of the patients with AIS in the study by Singh et al [12] . Similarly, a significant increase in sNfL over the first 30 days was observed among patients with AIS due to non-traumatic vertebral or carotid artery dissection [14] . In contrast, over the first 6 days of AIS, no significant sNfH increase was observed among 16 patients with AIS, although statistical power was probably too low to detect an increase in sNfH over time [13] . Among 27 patients with acute spinal injury, sNfL increased steadily over the first 7 days [6] . Overall, these findings point to a delayed increase of sNfL in serum after AIS or TIA, making sNf unviable as an acute ischemic marker in the emergency setting despite its alluring pathophysiological pathway. In contrast, sNfL seems to be a promising marker for chronic diseases of the central nervous system, such as multiple sclerosis [15] , amyotrophic lateral sclerosis [16] and frontotemporal dementia [4] . For instance, in multiple sclerosis, sNfL is associated with gadolinium-enhancing lesions, Expanded Disability Status Scale assessments, risk of relapses and disability progression [3] .
Among patients with AIS with poor functional outcome at 3 months, we found higher sNfL on admission, but the association was not significant after correction for age, NIHSS score and infarct size, similar to the previous study on patients with cervical artery dissection [14] . Another study found that poor functional outcome at 6 months was associated with higher sNfH levels drawn 3 weeks after AIS, but there was no adjustment for confounders [12] . Thus, sNfL does not seem to add prognostic information beyond established predictors such as NIHSS score and infarct size. In contrast, two previous prospective cohort studies showed that copeptin levels measured on blood drawn on admission reclassify 11.8% of patients with AIS for the prediction of 3-month disability and 37.2% for the prediction of 3-month mortality. The reason for the greater prognostic performance of copeptin compared with sNf may be the faster release of copeptin into the bloodstream, given that copeptin does not need to cross the bloodbrain barrier, as it is secreted into the bloodstream from the posterior pituitary gland [17, 18] .
The strengths of this work are the large sample size, inclusion of patients with symptom onset within 24 h and discrimination of AIS from TIA based on MR-DWI acquired on admission. The present study has limitations. First, the number of longitudinal samples in time was too small to reliably assess the dynamic of sNfL, and only part of the patients treated with thrombolysis received a second venipuncture for sNfL. Thrombolysis may have mitigated axonal damage and, consequently, the rise of sNfL over the first 24 h since admission. We aimed, however, to primarily assess sNfL as a blood marker in the emergency situation. Secondly, measurement of infarct size was semi-quantitative, although based on a published and validated method. However, even the discrimination ability of sNfL between TIA and AIS (i.e. absence vs. presence of an infarct on MR-DWI) was moderate, bringing into question the clinical relevance of sNfL drawn within 24 h after symptom onset. Thirdly, in order to quantify sNfL, the electrochemiluminescence assay was used instead of the newly developed single-molecule array (Simoa) method. For serum measurements, however, sNfL was reported to be highly correlated between the electrochemiluminescence assay and Simoa (Spearman correlation coefficient, 0.86, P < 0.001) [2] In conclusion, among patients admitted within 24 h of AIS or TIA onset, sNfL was associated with clinical severity on admission, but not with infarct size on MR-DWI acquired on admission or functional outcome at 3 months. The delayed increase of sNfL levels probably makes sNfL unviable as an acute ischemic marker, at least when measured in blood drawn as early as 24 h after symptom onset. Given the growing interest in the clinical role of sNfL in many neurological diseases, these findings bring new patient-oriented evidence on the role of sNfL among patients admitted with acute cerebrovascular events.
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